Objective:To evaluate the efficacy and safety profile of first-line bevacizumab (Bev)-containing pemetrexed-platinum chemotherapy in a real-world Chinese cohort with advanced non-squamous non-small cell lung cancer (NS-NSCLC).Methods:A total of 415 eligible patients with NS-NSCLC who received first-line pemetrexed-platinum chemotherapy at National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College between February 2010 and September 2017 were reviewed retrospectively:309 Bev(-) and 106 Bev(+) cases.Bev was administered at 7.5 mg/kg every 3 weeks in the Bev(+) group.To reduce the risk of a selection bias,a propensity score-matching (PSM) was conducted and 105 pairs of Bev(-) and Bev(+) cases were identified.Results:The median duration of follow-up was 15.8 months.The median progression-free survival (PFS) was prolonged significantly in the Bev(+) group than in the Bev(-) group in overall (9.8 vs.7.8 months,P=0.006) and PSM pairs (9.8 vs.6.6 months,P＜0.001).Moreover,patients receiving maintenance therapy with pemetrexed plus Bev had longer PFS than those interrupted after induction chemotherapy,or those receiving mono-maintenance with pemetrexed (12.3 vs.4.8 vs.8.6 months;P＜0.001).Multivariate analyses revealed Bev to be one of the favorable prognostic factors for PFS,along with the predictor of maintenance therapy.Conclusions:First-line induction and maintenance therapy with Bev (7.5 mg/kg every 3 weeks) combined with pemetrexed-platinum chemotherapy was efficacious and superior to non-Bev chemotherapy in Chinese patients with advanced NS-NSCLC.